EuroMRD ALL KMT2A 2025 (for testing)

EuroMRD ALL KMT2A EQA scheme 2025

Task 5: KMT2A-based RQ-PCR

The section for RQ-PCR based minimal residual disease (MRD) assessment in KMT2A-rearranged acute lymphoblastic leukemia (ALL) is performed once a year. KMT2A-rearrangements serve as RQ-PCR target, and KMT2A-rearranged samples together with the respective KMT2A-rearrangement sequence are provided to participants. Each EQA round consists of one mandatory target that is evaluated and scored, optionally being supplemented by a second more challenging target (not scored), which is included for educational reasons and provides a basis for discussion.

The analysis of MRD data should be undertaken as detailed in the instructions provided by the organizers and in accordance with the EuroMRD guidelines.

Performance evaluation and report

Certificates of participation and performance in EQA rounds will be distributed after the EuroMRD meeting of the same calendar year. Performance criteria of the ALL KMT2A scheme: a certificate will be provided if at least 75% of points have been received, otherwise only a certificate of attendance will be provided for this task.

EQA Educational meeting

During the ESLHO week in November, the annual EuroMRD meeting is organized. At this meeting, the results of all EuroMRD EQA schemes are shown (anonymized) and discussed with all EuroMRD participants, in small discussion groups as well as during plenary sessions.

Organization

The ALL KMT2A EQA scheme is organized by ESLHO (EQA Program Coordinator: Prof. Dr. Jacques J.M. van Dongen) in collaboration with the EuroMRD EQA Committee (ALL KMT2A scheme lead: Giovanni Cazzaniga). The members of the EuroMRD EQA Committee are participants of the EuroMRD Consortium. The EuroMRD subject-matter experts provide support for:

• Pre-round: Case selection, determination of consensus results

• Post-round: Data analysis, performance evaluation, reporting

Task division